Diagnostic Utility of Integration of Dynamic Contrast-Enhanced and Dynamic Susceptibility Contrast MR Perfusion Employing Split Bolus Technique in Differentiating High-Grade Glioma

Virender Malik; Chandrasekharan Kesavadas; Bejoy Thomas; Deepti A. N.; Krishna Kumar K.

doi:10.1055/s-0043-1777742

Indian Journal of Radiology and Imaging, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Indian J Radiol Imaging 2024; 34(03): 382-389
DOI: 10.1055/s-0043-1777742

Original Article

Diagnostic Utility of Integration of Dynamic Contrast-Enhanced and Dynamic Susceptibility Contrast MR Perfusion Employing Split Bolus Technique in Differentiating High-Grade Glioma

Virender Malik

¹Army Hospital (Research & Referral), Delhi, India

,

Chandrasekharan Kesavadas

²Department of Imaging Sciences and Interventional Radiology, Sree Chitra Tirunal Institute for Medical Sciences & Technology, Thiruvananthapuram, India

,

Bejoy Thomas

²Department of Imaging Sciences and Interventional Radiology, Sree Chitra Tirunal Institute for Medical Sciences & Technology, Thiruvananthapuram, India

,

Deepti A. N.

³Department of Pathology, Sree Chitra Tirunal Institute for Medical Sciences & Technology, Thiruvananthapuram, India

,

Krishna Kumar K.

⁴Department of Neurosurgery, Sree Chitra Tirunal Institute for Medical Sciences & Technology, Thiruvananthapuram, India

› Institutsangaben

Abstract

Background: Despite documented correlation between glioma grades and dynamic contrast-enhanced (DCE) magnetic resonance (MR) perfusion-derived parameters, and its inherent advantages over dynamic susceptibility contrast (DSC) perfusion, the former remains underutilized in clinical practice. Given the inherent spatial heterogeneity in high-grade diffuse glioma (HGG) and assessment of different perfusion parameters by DCE (extravascular extracellular space volume [Ve] and volume transfer constant in unit time [k-trans]) and DSC (rCBV), integration of the two into a protocol could provide a holistic assessment. Considering therapeutic and prognostic implications of differentiating WHO grade 3 from 4, we analyzed the two grades based on a combined DCE and DSC perfusion.

Methods: Perfusion sequences were performed on 3-T MR. Cumulative dose of 0.1 mmol/kg of gadodiamide, split into two equal boluses, was administered with an interval of 6 minutes between the DCE and DSC sequences. DCE data were analyzed utilizing commercially available GenIQ software.

Results: Of the 41 cases of diffuse gliomas analyzed, 24 were WHO grade III and 17 grade IV gliomas (2016 WHO classification). To differentiate grade III and IV gliomas, Ve cut-off value of 0.178 provided the best combination of sensitivity (88.24%) and specificity (87.50%; AUC: 0.920; p < 0.001). A relative cerebral blood volume (rCBV) of value 3.64 yielded a sensitivity of 70.59% and specificity of 62.50% (p = 0.018). The k-trans value, although higher in grade III than in grade IV gliomas, did not reach statistical significance (p = 0.108).

Conclusion: Uniqueness of employed combined perfusion technique, treatment naïve patients at imaging, user-friendly postprocessing software utilization, and ability of Ve and rCBV to differentiate between grade III and IV gliomas (p < 0.05) are the strengths of the present study, contributing to the existing literature and moving a step closer to achieving accurate MR perfusion-based glioma grading.

Keywords

combined perfusion technique - split bolus contrast - grade III from grade IV glioma

Volltext

Referenzen

References
1 Jahng GH, Li KL, Ostergaard L, Calamante F. Perfusion magnetic resonance imaging: a comprehensive update on principles and techniques. Korean J Radiol 2014; 15 (05) 554-577
2 Singh IN, Sullivan PG, Hall ED. Peroxynitrite-mediated oxidative damage to brain mitochondria: Protective effects of peroxynitrite scavengers. J Neurosci Res 2007; 85 (10) 2216-2223
3 Lacerda S, Law M. Magnetic resonance perfusion and permeability imaging in brain tumors. Neuroimaging Clin N Am 2009; 19 (04) 527-557
4 Patankar TF, Haroon HA, Mills SJ. et al. Is volume transfer coefficient (K(trans)) related to histologic grade in human gliomas?. Am J Neuroradiol 2005; 26 (10) 2455-2465
5 Essig M, Shiroishi MS, Nguyen TB. et al. Perfusion MRI: the five most frequently asked technical questions. Am J Roentgenol 2013; 200 (01) 24-34
6 Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. eds. WHO Classification of Tumours of the Central Nervous System. Rev. 4th ed. Geneva: World Health Organization; 2016
7 Louis DN, Ohgaki H, Wiestler OD. et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114 (02) 97-109
8 Weller M, van den Bent M, Hopkins K. et al; European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 2014; 15 (09) e395-e403
9 Johnson DR, Guerin JB, Giannini C, Morris JM, Eckel LJ, Kaufmann TJ. 2016 updates to the WHO brain tumor classification system: what the radiologist needs to know. Radiographics 2017; 37 (07) 2164-2180
10 Barker II FG, Chang SM, Huhn SL. et al. Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 1997; 80 (05) 936-941
11 Spampinato MV, Smith JK, Kwock L. et al. Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. Am J Roentgenol 2007; 188 (01) 204-212
12 Batra A, Tripathi RP, Singh AK. Perfusion magnetic resonance imaging and magnetic resonance spectroscopy of cerebral gliomas showing imperceptible contrast enhancement on conventional magnetic resonance imaging. Australas Radiol 2004; 48 (03) 324-332
13 Calli C, Kitis O, Yunten N, Yurtseven T, Islekel S, Akalin T. Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors. Eur J Radiol 2006; 58 (03) 394-403
14 Santarosa C, Castellano A, Conte GM. et al. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis. Eur J Radiol 2016; 85 (06) 1147-1156
15 Kimura M, da Cruz Jr LCH. Multiparametric MR imaging in the assessment of brain tumors. Magn Reson Imaging Clin N Am 2016; 24 (01) 87-122
16 Jain R, Gutierrez J, Narang J. et al. In vivo correlation of tumor blood volume and permeability with histologic and molecular angiogenic markers in gliomas. Am J Neuroradiol 2011; 32 (02) 388-394
17 Jiang W, Huang Y, An Y, Kim BYS. Remodeling tumor vasculature to enhance delivery of intermediate-sized nanoparticles. ACS Nano 2015; 9 (09) 8689-8696
18 Armitage P, Behrenbruch C, Brady M, Moore N. Extracting and visualizing physiological parameters using dynamic contrast-enhanced magnetic resonance imaging of the breast. Med Image Anal 2005; 9 (04) 315-329
19 Armitage PA, Farrall AJ, Carpenter TK, Doubal FN, Wardlaw JM. Use of dynamic contrast-enhanced MRI to measure subtle blood-brain barrier abnormalities. Magn Reson Imaging 2011; 29 (03) 305-314
20 Artzi M, Liberman G, Nadav G. et al. Human cerebral blood volume measurements using dynamic contrast enhancement in comparison to dynamic susceptibility contrast MRI. Neuroradiology 2015; 57 (07) 671-678
21 Lev MH, Ozsunar Y, Henson JW. et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. Am J Neuroradiol 2004; 25 (02) 214-221
22 Hoefnagels FW, Lagerwaard FJ, Sanchez E. et al. Radiological progression of cerebral metastases after radiosurgery: assessment of perfusion MRI for differentiating between necrosis and recurrence. J Neurol 2009; 256 (06) 878-887
23 Tofts PS, Brix G, Buckley DL. et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999; 10 (03) 223-232
24 Mills SJ, Soh C, Rose CJ. et al. Candidate biomarkers of extravascular extracellular space: a direct comparison of apparent diffusion coefficient and dynamic contrast-enhanced MR imaging: derived measurement of the volume of the extravascular extracellular space in glioblastoma multiforme. AJNR Am J Neuroradiol 2010; 31 (03) 549-553
25 Alcaide-Leon P, Pareto D, Martinez-Saez E, Auger C, Bharatha A, Rovira A. Pixel-by-pixel comparison of volume transfer constant and estimates of cerebral blood volume from dynamic contrast-enhanced and dynamic susceptibility contrast-enhanced MR imaging in high-grade gliomas. Am J Neuroradiol 2015; 36 (05) 871-876
26 Shin JH, Lee HK, Kwun BD. et al. Using relative cerebral blood flow and volume to evaluate the histopathologic grade of cerebral gliomas: preliminary results. Am J Roentgenol 2002; 179 (03) 783-789
27 Bulakbasi N, Kocaoglu M, Farzaliyev A, Tayfun C, Ucoz T, Somuncu I. Assessment of diagnostic accuracy of perfusion MR imaging in primary and metastatic solitary malignant brain tumors. Am J Neuroradiol 2005; 26 (09) 2187-2199
28 Law M, Yang S, Babb JS. et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004; 25 (05) 746-755
29 Al-Okaili RN, Krejza J, Woo JH. et al. Intraaxial brain masses: MR imaging-based diagnostic strategy—initial experience. Radiology 2007; 243 (02) 539-550
30 Aydin S, Fatihoğlu E, Koşar PN, Ergün E. Perfusion and permeability MRI in glioma grading. Egypt J Radiol Nucl Med 2020; 51 (02) 1-8
31 Zhang Y, Wang J, Wang X, Zhang J, Fang J, Jiang X. Feasibility study of exploring a T₁-weighted dynamic contrast-enhanced MR approach for brain perfusion imaging. J Magn Reson Imaging 2012; 35 (06) 1322-1331
32 Xyda A, Haberland U, Klotz E. et al. Diagnostic performance of whole brain volume perfusion CT in intra-axial brain tumors: preoperative classification accuracy and histopathologic correlation. Eur J Radiol 2012; 81 (12) 4105-4111
33 Jia ZZ, Gu HM, Zhou XJ. et al. The assessment of immature microvascular density in brain gliomas with dynamic contrast-enhanced magnetic resonance imaging. Eur J Radiol 2015; 84 (09) 1805-1809
34 Li X, Zhu Y, Kang H. et al. Glioma grading by microvascular permeability parameters derived from dynamic contrast-enhanced MRI and intratumoral susceptibility signal on susceptibility weighted imaging. Cancer Imaging 2015; 15 (01) 4
35 Abe T, Mizobuchi Y, Nakajima K. et al. Diagnosis of brain tumors using dynamic contrast-enhanced perfusion imaging with a short acquisition time. Springer Plus. Springer Plus 2015; 4 (88) 1-6 PubMed
36 Jelescu IO, Leppert IR, Narayanan S, Araújo D, Arnold DL, Pike GB. Dual-temporal resolution dynamic contrast-enhanced MRI protocol for blood-brain barrier permeability measurement in enhancing multiple sclerosis lesions. J Magn Reson Imaging 2011; 33 (06) 1291-1300
37 Li KL, Buonaccorsi G, Thompson G. et al. An improved coverage and spatial resolution: using dual injection dynamic contrast-enhanced (ICE-DICE) MRI: a novel dynamic contrast-enhanced technique for cerebral tumors. Magn Reson Med 2012; 68 (02) 452-462
38 Miyati T, Banno T, Mase M. et al. Dual dynamic contrast-enhanced MR imaging. J Magn Reson Imaging 1997; 7 (01) 230-235
39 Thompson EM, Guillaume DJ, Dósa E. et al. Dual contrast perfusion MRI in a single imaging session for assessment of pediatric brain tumors. J Neurooncol 2012; 109 (01) 105-114